- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different" Episode 3: Pricing
Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA, who joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.
In our first 2 episodes, we brought you multi-stakeholder discussions of biosimilar interchangeability and nonmedical switching.
Today, we’re changing gears and bringing you a perspective from the business side of biosimilars. Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA.
Van Lieshout is a consultant with 37 years of experience in developing market access strategies for pharmaceutical companies. Most recently, Van Lieshout worked in the Apotex family of companies, as vice president of trade and industry relations for Apobiologix. He joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
